MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Income from Non-Controlling Interests of $77000.0 for Q1 2026, up 112.52% year-over-year from $36231.8 in Q1 2025, and up 102.84% quarter-over-quarter from -$2.7 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $77000.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 112.52% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at -$4.4 million (down 399.12% YoY), while the FY2025 annual figure was -$5.1 million, down 290.73% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $77000.0, up from -$2.7 million in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $9.4 million in Q4 2023, with the low at -$5.3 million in Q2 2022.
- The 5-year median for Income from Non-Controlling Interests is $50736.0 (2023), against an average of $320810.7.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests soared 4363.67% in 2023, then plunged 437.91% in 2025.
- MoonLake Immunotherapeutics' Income from Non-Controlling Interests stood at $639890.0 in 2022, then jumped by 1368.78% to $9.4 million in 2023, then tumbled by 76.84% to $2.2 million in 2024, then slumped by 224.53% to -$2.7 million in 2025, then surged by 102.84% to $77000.0 in 2026.
- Business Quant data shows MLTX's Income from Non-Controlling Interests at $77000.0 in Q1 2026, -$2.7 million in Q4 2025, and -$965000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | 77,000.00 |
| Dec 31, 2025 | -2.71 Mn |
| Sep 30, 2025 | -965,000.00 |
| Jun 30, 2025 | -831,000.00 |
| Mar 31, 2025 | -615,000.00 |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | -733,000.00 |
| Jun 30, 2024 | 652,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 9.40 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | -415,225.00 |
| Mar 31, 2023 | 24,472.00 |
| Dec 31, 2022 | 639,890.00 |
| Sep 30, 2022 | 77,006.00 |
| Jun 30, 2022 | -5.26 Mn |